Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
24 April 2020updated 06 Oct 2020 9:45am

Antiviral drug remdesivir fails first randomised clinical trial, according to WHO document

By Samuel Horti

Remdesivir, the antiviral drug that many hoped could treat Covid-19, has failed its first randomised clinical trial, according to draft documents accidentally published by the World Health Organization (WHO).

The drug had shown promise in early testing, but a Chinese trial showed that it did not improve patients’ condition or reduce the level of coronavirus in their bloodstreams.

According to the WHO document, scientists gave the drug to 158 people, and gave the remaining 79 a placebo. After a month, 13.9 per cent of patients taking the drug had died compared to 12.8 per cent of the placebo group. The trial was stopped early because of side-effects from the drug.

The company behind the drug, Gilead Sciences, said the document had mischaracterised the study. Trading of its shares was temporarily halted after investors dumped stock.

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A weekly dig into the New Statesman’s archive of over 100 years of stellar and influential journalism, sent each Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy